In two other large, randomised, double-blinded phase 3 trials, the European Cooperative Acute Stroke study (ECASS) and ECASS-II, IV r-tPA was not more effective than placebo in improving neurological outcomes 90 days after stroke.7,9 A dose of 1.1 mg/kg of IV r-tPA was used in ECASS and a dose of 0.9 mg/kg was used in ECASS II. The gene discussed is PLAT; the disease is Stroke.